Gene Therapy Trial for Mitochondrial Disease of Retina Found Safe, Can Continue

Print Friendly, PDF & Email

An independent Data Safety Monitoring Board (DSMB) has found GS030 , GenSight Biologics ’ candidate gene therapy for retinitis pigmentosa , safe and recommended the company’s PIONEER trial continue as planned. PIONEER ( NCT03326336 ) is a Phase 1/2 trial currently investigating the safety and tolerability of increasing doses […]